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Objective: This study evaluated and compared the midterm results of endovascular aortic aneurysm repair with the
Endurant (Medtronic Inc, Santa Rosa, Calif) stent graft system in off-label use in patients with short (<10 mm) proximal
aortic necks and in patients treated according to device-speciﬁc instructions for use.
Methods: This was a case-control (2:1) single-center retrospective analysis of prospectively collected data performed
between September 2008 andDecember 2012. Analysis identiﬁed 19 elective patients with short (<10mm) proximal necks
and mild angulations (#45) treated with the Endurant stent graft and 38 patients matched for age, sex, and aneurysm
diameter with proximal aortic necks$10mm in length whomet the instructions for use. End points included technical and
clinical success and freedom from any secondary intervention, any type of endoleak, and aneurysm-related death.
Results: The short-neck group was a mean 6 standard deviation age of 71.7 6 8.9 years, 84% were men, and their mean
infrarenal aortic neck length was 6.1 6 1.2 mm. Mean suprarenal and infrarenal angles were 110 6 10.4 and 170 6
15.4, respectively. Aortic neck diameters were similar between the groups (26.6 6 3.8 vs 25.7 6 3.7 mm; P [ .36).
Primary technical success was achieved in all cases. Off-label patients were more likely to require additional proximal cuff
deployment to successfully obtain a seal (21% vs 3%; P [ .04). The two patient groups were similar in rates of periop-
erative mortality, morbidity, and complications. Mean follow-up of 24 6 12 months revealed no differences in clinical
success, freedom from reintervention, and aneurysm-related death. No type I endoleaks were observed in either group
during the follow-up period.
Conclusions: The Endurant stent graft system applied off-label in patients with very short aneurysm necks (<10 mm) with
mild angulation showed acceptable treatment results. These midterm results might suggest its use in carefully selected
patients with very short neck anatomy. Long-term data are needed to verify the observed durability of the Endurant stent
graft. (J Vasc Surg 2015;61:9-15.)Endovascular aortic aneurysm repair (EVAR) has
gained wide acceptance as the preferred method of treat-
ment by physicians and patients and accounts for more
than half of all abdominal aortic aneurysm (AAA) repairs.1
This less invasive technique is associated with lower periop-
erative risks than open surgical repair, but reintervention
rates are higher.2 Despite the technologic advancements
of new stent graft devices, several anatomic criteria still
require consideration before planning for EVAR.
The presence of a proximal neck <10 mm represents
an independent risk factor for periprocedural and late
complications after EVAR.3 Open surgical repair or endo-
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://dx.doi.org/10.1016/j.jvs.2014.07.002grafts has been proposed for these patients. However, sig-
niﬁcant comorbidities can limit open procedures, and the
use of custom-made fenestrated devices is restricted to
centers with expertise as well as by delays in availability
due to complex manufacturing.4 Branched off-the-shelf
solutions are still under development, and their long-
term results need to be better established. Despite the initial
technical success, the “chimney” technique also lacks
medium-term and long-term follow-up data. The need to
treat high-risk patients with hostile aortic neck anatomies
has extended the use of the stent grafts even in off-label con-
ditions, although a higher risk of type I endoleaks has been
reported.5,6
The Endurant endograft (Medtronic Inc, Santa Rosa,
Calif) is a new-generation device for AAA repair that has
been speciﬁcally developed to conform to challenging anato-
mies, thus allowing a broader group of patients to be treated
with EVAR.7 The combination of an M-shaped conﬁgura-
tion of nitinol stents and improved suprarenal active ﬁxation
provides potentially greater ﬂexibility and resistance to
migration in shorter proximal aortic neck lengths.
The overall purpose of this study was to evaluate
the midterm results of EVAR using the Endurant stent
graft system in patients with proximal aortic neck
lengths <10 mm. Speciﬁcally, we assessed technical and
clinical outcomes in this off-label group and compared9
Fig 1. A, A three-dimensional volume-rendered computed tomography reconstruction. B, Analysis of the center
lumen line shows the absolute length of the neck. C, Intraoperative digital subtraction angiography shows the accurate
deployment of the stent graft just below the lowest right renal artery. D, A computed tomography scan at 12 months
shows no signs of endoleak.
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the device-speciﬁc instructions for use (IFU).METHODS
The University of Ioannina Medical School Institu-
tional Review Committee approved this study.
Study design and patient selection. A case-control
study was conducted to assess the efﬁcacy and safety of
EVAR in very short (<10 mm) proximal AAA necks using
the Endurant stent graft system in an off-label situation.
Between September 2008 and December 2012, 265 pa-
tients with an infrarenal AAA were treated with EVAR in
our center, and 181 were electively treated with the
Endurant stent graft. A dedicated database was established
to prospectively collect patient data that included de-
mographics, preoperative risk factors, operative time, blood
loss, contrast media use, patient outcomes, length of stay,
and complications.
The manufacturer’s IFU recommend a proximal aortic
neck length $10 mm with #60 infrarenal angulation or a
proximal aortic neck $15 mm with #75 infrarenal angu-
lation. The favorable delivery and deployment characteris-
tics of the Endurant stent graft system for enhanced
proximal landing suggested it could be efﬁcacious in pa-
tients with proximal necks <10 mm without excessive an-
gulations (always #45) who were high-risk for open
repair. Patients were given the option of an open surgical
procedure rather than EVAR with off-label use of the de-
vice and were informed of the potential risks and beneﬁts
of each option. All patients signed the hospital’s informed
consent form before the procedure.
Sizing and planning before EVAR were performed using
a workstation with Osirix (Pixmeo, Bernex, Switzerland)
or 3Mensio (Medical Imaging B.V., Bilthoven, The
Netherlands) dedicated reconstruction software by the
same operator (M.M.). The length of the proximal neck
was deﬁned as the distance between the distal end of the
oriﬁce of the lowest renal artery and the beginning of the
aneurysm measured in stretched anatomy using the center
lumen line (Fig 1).All procedures were performed in an adequately equip-
ped operating room with the patient under general or
regional anesthesia and surgical cutdown of both femoral
arteries, using a BV Pulsera 12” mobile ﬂuoroscopic C-
arm unit (Philips Healthcare, Best, The Netherlands) and
a radiographic carbon table equipped with side-table
shielding (Varay Laborix, Bourges, France).
Patients were discharged in the absence of any compli-
cations, with a body temperature of <37.5C for at least
24 hours and a white blood cell count <12,000/mL. All
patients underwent a postoperative surveillance protocol
at 1, 6, 12, and 24 months that included a physical exam-
ination, blood pressure measurement, and computed to-
mography angiography (Fig 2). To stratify patients
according to their risk status for open repair, we used the
well-validated Glasgow aneurysm score and chose a cutoff
of 70 to characterize a patient as unﬁt for open repair.8
Short-neck off-label group. During the study period,
19 patients were identiﬁed with proximal neck
lengths <10 mm and both suprarenal and infrarenal angles
#45 were treated with the Endurant stent graft. These pa-
tients accounted for 10.5% of operations with the same de-
vice and 7.2% of all elective EVARs at the same time period.
Control IFU group. The control group was selected
from the sample of elective infrarenal EVARs using the
same device during the same period as the off-label
group. For homogeneity, the study excluded patients
with severe angulations, deﬁned as an infrarenal angle >75
or a suprarenal angle >60, or both, combined with a neck
length of $15 mm, or an infrarenal angle >60 or supra-
renal angle >45, or both, combined with neck length
>10 mm. To include a control group with the least se-
lection bias, after the original cohort was formed, one of
the investigators (G.K.), blinded to patient data apart from
age, sex, and AAA diameter, matched the 19 patients from
the off-label group 2:1 with individuals from the cohort
treated with the Endurant endograft within the device IFU
without severe angulation (142 patients) for age
(#2 years), sex, and AAA diameter (#1 cm). The ﬁnal
population of this analysis included 57 patients, 19 in the
off-label group and 38 in the control group.
Fig 2. A, Three-dimensional volume-rendered computed tomography reconstruction of the aneurysm proximal neck.
B, Analysis of the center lumen line shows the absolute length of the neck. C, Computed tomography angiography
reconstruction 2 years after the procedure.
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reporting standards according to the guidelines from
the Society for Vascular Surgery/American Association
for Vascular Surgery were used.9 Technical success was
deﬁned as successful deployment of the endograft in the
intended anatomic position and completion of the proce-
dure with no type I or III endoleaks and without the need
for a secondary intervention within the ﬁrst 24 hours.
Clinical success was deﬁned as freedom from aneurysm
expansion >5 mm, type I or III endoleaks, aneurysm
rupture, conversion to open surgery, graft infection, migra-
tion, or thrombosis, and aneurysm-related death during
follow-up periods.
Statistical analysis. Data are expressed as mean 6
standard deviation except for non-Gaussian parameters
that are presented as median and interquartile range (IQR).
Categoric data are presented by absolute values and per-
centages (%). Statistical signiﬁcance between the groups for
continuous variables used the independent t-test for nor-
mally distributed data or the Mann-Whitney U test for
nonparametric data. The Pearson c2 test or the Fisher exact
test was used for categoric variables, as appropriate.
Midterm follow-up data were analyzed by Kaplan-Meier
life-table analysis, and results were compared by the log-
rank test. Statistical analyses used SPSS 20.0 software
(IBM Corp, Armonk, NY). A P value of <.05 was
considered statistically signiﬁcant.
RESULTS
Patient demographic data and preoperative risk factors
are summarized in Table I. The short-neck group (84%
males) was a mean age of 71.7 6 8.9 years. No signiﬁcant
differences in comorbidities or physical status were noted be-
tween the two groups. According to the Glasgow aneurysm
score, Thirteen patients (68%) in the off-label group had a
Glasgow aneurysm score >70 and were considered high-
risk for open repair. Six patients, although ﬁt for open repair,
preferred EVAR for their aneurysmal treatment.Table II summarizes aneurysm assessments. The mean
aortic neck length was 6.1 6 1.2 mm (median, 6; range,
5-8 mm) in the off-label group and 16.1 6 3 mm (median,
15; range 14-19.3 mm) in the IFU group (P < .001). The
mean maximum diameter of the aneurysm in the respective
groups was 5.76 0.6 cm vs 5.86 0.8 cm (P ¼ .59). Aortic
neck diameters also were similar between the two groups
(26.6 6 3.8 mm vs 25.7 6 3.1 mm; P ¼ .36). Angulations
of the proximal neck did not differ signiﬁcantly between
groups, although a tendency toward a wider infrarenal
angle was noted in the IFU group (P ¼ .07). Neck circum-
ferential characteristics of >30% thrombus or >30% calciﬁ-
cation also were statistically similar.
Perioperative data are outlined in Table III. General
anesthesia was used most often. Local or regional anes-
thesia was used in three short-neck patients and in ﬁve con-
trol patients (P ¼ .54). The median operating times were
85 and 82.5 minutes, respectively (P ¼ .48). Radiation
burden and volume of contrast media did not differ signif-
icantly between the groups.
Primary technical success was achieved in all cases. Four
off-label patients (21%) required additional proximal cuff
placement to successfully obtain a seal or to use the full
length of the neck compared with one patient (3%) in
the IFU group (P ¼ .04). Two of the four patients of
the off-label group had a type I endoleak intraoperatively,
whereas in the other two, we wanted to use the full length
of the short neck for the proximal landing zone in the
absence of an endoleak. The patient of the control group
had a type I endoleak. None of the patients required the
use of renal stenting due to questionable renal coverage.
All renal arteries were patent at the completion
angiography.
No intraoperative conversions, migrations, type I or III
endoleak at the completion angiogram, or deaths were
recorded at the end of the procedure. One patient in the
control group developed a minor stroke on postoperative
day 3. Postimplantation syndrome was encountered in
Table I. Demographics and perioperative data
Baseline characteristicsa
Short neck Control
P value
Off-label
(n ¼ 19)
IFU
(n ¼ 38)
Demographics
Age, years 71.76 8.9 71.6 6 6.8 .97
Male gender 16 (84) 34 (90) .10
Perioperative risk factors
Hypertension 18 (95) 36 (95) .44
Coronary artery disease 12 (63) 19 (50) .25
COPD 9 (47) 23 (61) .15
Hyperlipidemia 14 (74) 33 (87) .19
Diabetes 4 (21) 8 (21) .62
Cardiac failure 4 (21) 6 (16) .37
Smoking 11 (58) 24 (63) .45
ASA class 3/4 14 (74) 26 (69) .19
ASA class, American Society of Anesthesiologists Physical Status Classiﬁcation;
COPD, chronic obstructive pulmonary disease; IFU, instructions for use.
aContinous data are shown as the mean 6 standard deviation and categoric
data as number (%).
Table II. Preoperative aneurysm diagnostic assessment
Measurements
Short neck Control
P valueOff-label (n ¼ 19) IFU (n ¼ 38)
Neck length, mm <.001
Mean 6 SD 6.1 6 1.2 16.1 6 3.1
Median (IQR) 6 (5-8) 15 (14-19.3)
Maximum aneurysm
diameter, mean 6
SD mm
5.7 6 0.6 5.8 6 0.8 .59
Neck diameter,
mean 6 SD mm
26.6 6 3.8 25.7 6 3.1 .36
Suprarenal angle
(a angle), median
(IQR)
8 (3-18) 6 (2.25-15) .54
Infrarenal angle
(b angle), median
(IQR)
10 (5-27) 15 (10-40) .07
Thrombus >30%,
No. (%)
3 (16) 5 (13) .54
Calciﬁcation >30%,
No. (%)
2 (11) 5 (13) .57
IFU, Instructions for use; IQR, interquartile range; SD, standard deviation.
Table III. Initial procedural data
Measurementsa
Short neck Control
P value
Off-label
(n ¼ 19)
IFU
(n ¼ 38)
Duration implant
procedure, min
90 6 29 99 6 50 .47
Contrast media, mL 108 6 56 89 6 37 .13
Radiation burden, mGy 105 6 53 104 6 83 .96
Aortic cuff placement 4 (21) 1 (3) .04
Postimplantation syndrome 7 (37) 13 (34) 1
Hospital length of stay, days 4 (2-16) 5 (3-10) .74
IFU, Instructions for use.
aContinuous data are presented as mean 6 standard deviation or median
(range) and categoric data as number (%).
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groups (P ¼ 1). Most patients were discharged on postop-
erative day 4, with a median hospital stay of 4 days (range,
2-16 days) in the off-label group and 5 days (range, 3-
10 days) in the IFU group (P ¼ .74).
During the mean midterm follow-up period of 24 6
12 months (median, 24; range, 6-48 months), one reinter-
vention was performed in a patient in the short-neck group
who sustained an iliac limb thrombosis 2 months after the
initial procedure. The patient was successfully treated with
a femoral-femoral crossover bypass. No graft-related deaths
were recorded. One patient in the off-label group died
10 months after the index procedure of an acute MI during
an unrelated cardiac operation.
No conversion to open repair or graft migration
occurred. Three type II endoleaks (one in the short-neck
group and two in the control group) were discovered dur-
ing the follow-up period and spontaneously resolved.
Freedom from any early or late intervention was 94.7%
(18 of 19) for the off-label group vs 100% for the IFU
group (log rank ¼ 2; P ¼ .16; Fig 3). Primary assisted clin-
ical success during midterm follow-up was 100% for both
groups. During the follow-up period, ﬁve patients (26%)
of the open-label group had a stable sac, whereas in the
remaining 14 (74%), there was aneurysm sac regression.
In the control group, 11 patients (29%) had a stable aneu-
rysm, and 27 (71%) had sac regression.
DISCUSSION
A short proximal aortic neck length has been associated
with limited eligibility for EVAR and higher rates of
adverse events.3,10 Data regarding the use of standard
EVAR in short-neck AAAs are scarce and mostly accrue
from reports that do not study short necks separately but
as part of hostile neck anatomy.10 Studies of the off-label
use of endovascular devices for treating patients not ﬁtfor open surgery and challenging the IFU indications of
speciﬁc devices have become more frequent in the last
3 years.3,5,6 In the present report, we speciﬁcally compared
EVAR outcomes with the Endurant stent graft system in
AAA patients with proximal aortic necks that were outside
and within the IFU.
The main features of the Endurant stent graft system
that permit AAA repair in patients with short proximal
necks have been described elsewhere.3,11 Brieﬂy, the
controlled release of the top stent ensures the exact and
very accurate proximal deployment just below the lowest
renal artery, and the suprarenal anchoring pins offer a
strong ﬁxation to the aortic wall, thus reducing the risk
for future migration. The IFU anatomic inclusion criteria
are broader compared with other devices and include pa-
tients with minimum proximal neck lengths of $10 mm.
The applicability of the Endurant stent graft has been thor-
oughly tested in several situations with hostile neck anat-
omy inside the IFU as well as off-label and shows
Fig 3. Kaplan-Meier analysis of freedom from any early or late
intervention was 94.7% (standard error, 0.05) for the off-label
group (blue line) vs 100% for the instructions for use (IFU) con-
trol (green line) group. One patient in the control group was lost
due to cardiac death at the 10-month follow-up interval.
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largest number of patients with challenging anatomy
treated with the Endurant stent graft and found no type
I endoleak or deaths at 30 days.
In this EVAR series, similar results for technical and
clinical success and mortality were noted in patients treated
inside the IFU as well as those treated off-label with very
short aortic necks. These results are in contrast to previous
published reports that showed signiﬁcant differences in
favor of patients with proximal neck lengths >15 mm
treated endovascularly.12,13 AbuRahma et al12 investigated
the inﬂuence of proximal neck length on standard EVAR
outcomes and found signiﬁcantly higher rates of early
and late type I endoleak in patients with necks <10 mm.
However, almost all of these patients were treated with
the previous generation stent grafts with infrarenal ﬁxations
requiring at least a >15 mm neck length. Torsello et al3
evaluated the Endurant stent graft under IFU indications
vs off-label in 56 patients with hostile neck anatomy (27
with necks <10 mm and 29 with severe angulations) and
found a greater risk for type I endoleak. Whether this
increased risk was a result of short neck length, severe
angulation, or both, cannot be concluded from their study.
The coexistence of several anatomic restrictions may affect
outcomes and eventually jeopardize the proximal seal.
Consequently, close surveillance is mandatory to detect
and treat late occurring type I endoleak.
Apart from proximal endoleak, short aortic necks have
also been reported to increase the risk for device migration.
Fulton et al14 showed a trend for short proximal necks to
predict migration, whereas Tonnessen et al15 found initial
neck length was shorter in patients with migration. Both
studies mostly used ﬁrst-generation stent grafts withoutactive ﬁxation, and migration was observed with mean
initial neck lengths of >20 mm. In contrast, the 1-year
data of the Endurant Stent Graft Natural Selection Global
Postmarket Registry (ENGAGE) reported a zero rate of
migration within the ﬁrst year after implantation.7 Clinical
results in the present study are consistent with the registry,
with no migrations noted in patients treated inside the IFU
and off-label.
Reintervention rates between the two patient groups
were not signiﬁcantly different. Similar to the use of prox-
imal aortic cuff extension in our short-neck patients, AbuR-
ahma et al12 also reported a more frequent need for
proximal aortic cuff extension in patients with short necks
and demonstrated that rates of freedom from late interven-
tion at 3 years were unaffected. Our results suggest similar
ﬁndings at a mean follow-up period of 2 years. In addition,
our ﬁndings are in accordance with the freedom from early
and late type 1 endoleaks at 1 year in a recently published
study demonstrating that late reinterventions were not
increased in patients treated in off-label situations with
the Endurant stent graft despite signiﬁcantly higher rates
of early and late type I endoleak.3 The presence of short
(<15 mm) proximal aortic necks have been reported to
increase 30-day mortality after EVAR without affecting
6-month survival.12 Torsello et al3 found no signiﬁcant
differences in estimated survival at 1 year between patients
treated off-label and inside the IFU with the Endurant
stent graft. The outcomes of the present study are consis-
tent with these data.
Several anatomic restrictions usually coexist in patients
with hostile proximal aortic neck anatomy who are deemed
unﬁt for EVAR. Most of the studies of hostile proximal
aortic necks report results of patients with a wide variety
of anatomic restrictions, making the study of individual fac-
tors difﬁcult. Severe angulation has been associated with
signiﬁcant technical difﬁculties and adverse short-term out-
comes.16,17 In our clinical experience, short proximal necks
are rarely seen together with severe angulation and are usu-
ally the only anatomic restriction present. Off-label EVAR
was offered only to patients with very short proximal necks
with no or only small infrarenal and suprarenal angulations
well below 45. In these patients, meticulous preoperative
planning is of utmost importance to take operative advan-
tage of this accessible anatomy. Proper cranial-caudal posi-
tion and angle of the C-arm can also facilitate repair. Our
ﬁndings suggest that with adequate sizing and appropriate
patient selection coupled with careful planning and execu-
tion, EVAR in patients with very short necks and mild an-
gulations can result in outcomes similar to those expected
for the general EVAR-treated population.
In our experience, a slight slip of the stent graft is
sometimes encountered during the initial deployment of
the main body. This minor dislodgement (1-3 mm) may
not have a negative effect in the presence of an adequate
neck length but may be crucial to the successful repair of
very short aortic necks. In our practice, we favorably use
proximal aortic cuffs to seal type IA endoleaks seen on
completion angiography or use the full length of the short
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endoleak. In that way, the proximal seal is accomplished
while the secure ﬁxation of the distal part of the aortic
cuff into the proximal part of the stent graft diminishes
the risk for stent migration. Patients in this study treated
off-label were more likely to require additional aortic cuff
placement than patients treated inside the IFU. None of
the four patients in the off-label group who required an
additional cuff proximally developed subsequent endoleaks
during follow-up.
Several other new techniques, such as fenestrated
endovascular repair (F-EVAR) and chimney graft tech-
nique (Ch-EVAR), have been used to treat short necks.
F-EVAR has been successfully applied in many complex
AAA anatomies, showing the same low mortality and
midterm durability as standard EVAR.10,18 However, the
deployment of fenestrated stent grafts are technically
demanding and incur a signiﬁcant cost and delay due to
custom manufacturing compared with standard devices.
To date, their use is limited to some centers of expertise
around the world and is not always accessible to most
AAA patients with neck anatomies outside the IFU.
Ch-EVAR, albeit initially proposed as a “bail-out”
approach after unintentional coverage of renal arteries dur-
ing EVAR, has recently gained interest for the treatment of
high-risk patients with short AAA necks.10,18 The proce-
dure has been associated with more type I endoleak,
increased rates of ischemic stroke (up to 6%), and has not
been validated long-term.10,19,20 Considering these limita-
tions, standard EVAR in off-label situations might be a
viable therapeutic option, especially in some patients
deemed unﬁt for open surgery.
Nevertheless, it seems reasonable, especially when a pa-
tient is treated outside the IFU, that an adjunctive second
plan to address a persistent type I endoleak at the end of
the initial procedure or during the follow-up period is
mandatory. Although such a complication did not occurr
in this series, we were always ready to extend the proximal
landing zone with a chimney graft if it was anatomically
feasible. Depending on the anatomy, the quality of the
aorta, and the exact location of the endoleak, an attempt
to secure the endograft using the Aptus system (Aptus
Endosystems, Sunnyvale, Calif) was also kept in mind. In
somewhat ﬁt patients and after taking into account their
own desire for a more deﬁnite solution, we also considered
elective open conversion. F-EVAR seems also to be a good
solution for treating a type I endoleak during the follow-up
period, although certain parameters, such as the center’s
experience and the manufacturing delay, should be
acknowledged.
The major limitations to the present study include its
retrospective nature and the relatively small number of
patients from a single institution. Despite this, all patients
selected for off-label EVAR were treated consecutively
with the same stent graft system under stable conditions,
and the case-controlled IFU group was matched 2:1 to
the off-label group. In any case, these results must be inter-
preted with caution until validated by larger studies. Themulticenter Endurant for Challenging Anatomy: Global
Experience (EAGLE) Registry is currently recruiting
patients throughout Europe. Findings from this registry
will shed additional information on AAA patients with
challenging neck anatomies and suggest whether the IFU
remains applicable or needs to be expanded.21
Although the initial midterm results are encouraging,
the present study was not to liberally propose standard
EVAR in every patient with a proximal neck
length <10 mm, especially because the option of F-EVAR
is available. However, at the present time, F-EVAR and
Ch-EVAR have been associated with increased operation
time, radiation burden, and contrast media use, signiﬁcantly
higher costs, and limited centers of expertise accessible to
most patients.10,18 In addition, there is no long-term
follow-up for these techniques that have the disadvantage
to intervene at least to renal arteries.18 Although long-term
data are needed, EVAR performed off-label appears to be
safe and efﬁcacious in carefully selected patients with metic-
ulous preoperative sizing and planning, especially when per-
formed in experienced centers.
CONCLUSIONS
The Endurant stent graft system applied off-label
showed acceptable results in treating patients with very
short aneurysm necks (<10 mm) and mild angulation.
No differences in type I endoleak, survival, or reinterven-
tion rates were observed compared with the matched con-
trol group. Although long-term data are needed to verify
durability, the midterm results are promising and might
suggest the use of this speciﬁc endograft in carefully
selected patients with very short neck anatomy when other
options are not available.
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